arrow
A

Andreas Hüttmann

University Duisburg-Essen
H指数:40
被引数:8,379

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

更正: Brentuximab vedotin联合化疗治疗一线系统性间变性大细胞淋巴瘤: 5年随访时ECHELON-2研究的亚组分析

2026-01-280
OAAI
Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans

使用3D CNNs在全身PET/CT扫描上预测弥漫性大B细胞淋巴瘤的2年进展时间

2025-11-280
OAAI
Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response

弥漫性大B细胞淋巴瘤的风险预测在结合基线PET特征与中期PET反应时得到改善。

2025-10-010
OAAI
Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

brentuximab vedotin联合化疗用于一线系统性间变性大细胞淋巴瘤的治疗:ECHELON-2研究5年随访的亚组分析

2025-08-010
OAAI
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trial

高级别经典霍奇金淋巴瘤患者在接受BrECADD与eBEACOPP治疗后的生育能力比较:一项多中心、随机、平行、开放标签、III期HD21试验的二次分析

2025-07-100
OAAI
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)

来那度胺联合利妥昔单抗、地塞米松、高剂量阿糖胞苷(ARA-C)和顺铂作为难治性或复发性侵袭性B细胞非霍奇金淋巴瘤的挽救治疗——一项开放标签、多中心I/II期研究(DSHNHL-R6)。

2025-04-150
OA
Validation of an Artificial Intelligence-Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell Lymphoma

基于人工智能的预测模型验证:使用5个外部PET/CT数据集的弥漫性大B细胞淋巴瘤

2024-10-033
PRE
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patients

使用FDG PET的人工智能方法预测弥漫性大b细胞淋巴瘤患者的治疗结果

2023-08-1213
OAAI
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma
2023-01-248
OAAI
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphoma
2022-11-3013
OAAI
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial
LEUKEMIA
IF13.4
2022-10-143
OAAI
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA

通过对循环肿瘤DNA中的相位变体进行靶向测序来增强对微小残留疾病的检测

2021-07-22191
OAAI
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials

FDG PET/CT检测侵袭性非霍奇金淋巴瘤患者初始分期中的骨髓受累: 前瞻性,多中心PETAL和OPTIMAL>60试验的结果

2021-04-2926
OAAI